National_Coverage_Determinations_Manual / Autologous Cellular Immunotherapy Treatment 110.22

Why This Topic Matters

It helps readers understand when Medicare recognizes this therapy as covered and how CMS frames the treatment within national coverage policy, which is important for documentation, billing, and payer review.

Article Sections

1. General

   Provides background on prostate cancer and the therapy discussed in the policy review. Summarizes the clinical and regulatory context for the coverage determination.

2. Indications and Limitations of Coverage

   Introduces the coverage framework addressed by the determination. Includes the covered and non-covered coverage categories and related policy notes.

3. Nationally Covered Indications

   States the service period and the Medicare coverage scope for the therapy under this determination. Describes the type of beneficiary population addressed by the policy.

4. Nationally Non-Covered Indications

   Identifies whether any nationally non-covered uses are listed in the determination.

5. Other

   Addresses additional policy handling for uses outside the main covered indication. Includes contractor-level discretion and review timing information.